Table 1.
Baseline characteristics and Mean Blur Rate in normal tension glaucoma group and control group including biometric results. Glaucomatous damage was graded into groups according to the visual field impairment30.
| Characteristics | NTG Number, mean ± SD | Control group Number, mean ± SD | P Value | |
|---|---|---|---|---|
| Number | 20 | 20 | ||
| Sex | Male | 7 | 7 | |
| Female | 13 | 13 | ||
| Age (years) | 70.9 ± 9.1 | 71.0 ± 8.5 | 0.95 | |
| SBP (mmHg) | 144.0 ± 11.3 | 145.2 ± 11.6 | 0.73 | |
| DBP (mmHg) | 81.8 ± 8.0 | 78.0 ± 7.9 | 0.14 | |
| HR (bpm) | 69.7 ± 13.4 | 72.6 ± 10.5 | 0.45 | |
| MRSE (dpt) | −0.7 ± 1.5 | −0.4 ± 1. 1 | 0.46 | |
| BCVA (LogMAR) | 0.05 ± 0.07 | 0.03 ± 0.01 | 0.6 | |
| AGDs | 1.3 ± 0.73 | — | ||
| PGA | 16 (80%) | |||
| PGA + BB | 3 (15%) | |||
| PGA + BB + AA + CAI | 1 (5%) | |||
| IOP (mmHg) | Under therapy | 12.85 ± 1.9 | ||
| No therapy (After washout) | 15.3 ± 2.2 | 15.6 ± 2.6 | 0.8 | |
| MD (dB) | −9.2 ± 6.5 | −1.46 ± 1.37 | < 0.001* | |
| Glaucoma grade | Mild | 7 (35%) | ||
| Moderate | 6 (30%) | |||
| Severe | 4 (20%) | |||
| NA | 3 (15%) | |||
| cp RNFL(μm) | 67.0 ± 8.5 | 95.5 ± 9.0 | < 0.001* | |
| MBR (AU) | MA | 11.36 ± 2.8 | 16.9 ± 2.9 | < 0.001* |
| MV | 24.9 ± 5.7 | 31.6 ± 5.6 | 0.001* | |
| MT | 6.7 ± 1.6 | 8.9 ± 2.0 | 0.001* |
(NTG) Normal tension glaucoma. (SD) Standard deviation. (MBR) Mean blur rate. (SBP) Systolic blood pressure. (DBP) Diastolic blood pressure. (HR) Heart rate. (bpm) Beats per minute. (BCVA) Best corrected visual acuity. (AGDs) Antiglaucomatous drugs. (PGA) Prostaglandin-analogue monotherapy. (PGA + BB) Combination of prostaglandin analogue and beta blocker. (PGA + BB + AA + CAI) Combination of prostaglandin analogue, beta blocker, alpha agonist and carbonic anhydrase inhibitor. (IOP) Intraocular pressure. (MD) Mean deviation of visual field. (NA) Not applicable. (cpRNFL) Circumpapillary retinal nerve fibre layer. (AU) Aberration units. (MA) MBR in all area of interest. (MV) MBR in area of big vessels. (MT) MBR in area of microvasculature. (*Marks statistical significance).